PMC:7441788 / 40977-41313
Annnotations
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T171 | 30-38 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T172 | 306-314 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T299 | 0-1 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
LitCovid-sample-PD-NCBITaxon
| Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
|---|---|---|---|---|---|
| T151 | 30-38 | Species | denotes | COVID-19 | NCBItxid:2697049 |
| T152 | 306-314 | Species | denotes | COVID-19 | NCBItxid:2697049 |
LitCovid-sample-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T280 | 0-336 | Sentence | denotes | A prospective study of HCQ on COVID-19 patients (13 cases) admitted to the ICU in France showed that the first daily dose of 800 mg/1 time for 1 day, and 200 mg/2 times/day for 7 days was recommended to maintain the HCQ treatment level (1–2 mg/l) based on physiologically pharmacokinetic (PBPK) models for COVID-19 patients in ICU [67]. |
LitCovid-sample-Pubtator
| Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
|---|---|---|---|---|---|
| 1491 | 39-47 | Species | denotes | patients | Tax:9606 |
| 1492 | 315-323 | Species | denotes | patients | Tax:9606 |
| 1506 | 23-26 | Chemical | denotes | HCQ | MESH:D006886 |
| 1507 | 216-219 | Chemical | denotes | HCQ | MESH:D006886 |
| 1528 | 30-38 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1529 | 306-314 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sample-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T163 | 30-38 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T164 | 306-314 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1491 | 39-47 | Species | denotes | patients | Tax:9606 |
| 1492 | 315-323 | Species | denotes | patients | Tax:9606 |
| 1506 | 23-26 | Chemical | denotes | HCQ | MESH:D006886 |
| 1507 | 216-219 | Chemical | denotes | HCQ | MESH:D006886 |
| 1528 | 30-38 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1529 | 306-314 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T280 | 0-336 | Sentence | denotes | A prospective study of HCQ on COVID-19 patients (13 cases) admitted to the ICU in France showed that the first daily dose of 800 mg/1 time for 1 day, and 200 mg/2 times/day for 7 days was recommended to maintain the HCQ treatment level (1–2 mg/l) based on physiologically pharmacokinetic (PBPK) models for COVID-19 patients in ICU [67]. |